Conclusion: Our data reveal a considerable "stage migration" towards earlier diagnosis of prostate cancer in Victoria and a large increase in the use of radical prostatectomy among men with clinically localised disease.
The Medical Journal of Australia ISSN: 0025-729X 3 June 2013 198 10 540-545 ©The Medical Journal of Australia 2013 www.mja.com.au Research he Victorian Cancer Registry estimates that the number of men diagnosed with cancer will increase by 75% in the next 10 years, largely due to prostate cancer -the most common cancer diagnosis in men.
1 Algorithms have been developed to calculate risk of prostate cancer progression at time of diagnosis for men with localised disease, classifying men into four groups: very low, low, intermediate and high risk of recurrence (Appendix 1; online at mja.com.au).
2,3 The National Comprehensive Cancer Network (NCCN) guidelines suggest that many men with very low-risk clinically localised disease should be managed with active surveillance; men with low-risk and intermediate-risk disease should be managed with active surveillance or with external beam radiation therapy (EBRT), radical prostatectomy (RP), brachytherapy, or a combination of these treatments; and men with high-risk disease should be managed with EBRT and androgen deprivation therapy (ADT), or EBRT, high dose rate brachytherapy and ADT, or RP and pelvic node dissection. 2 Few studies have compared the effectiveness of treatments for localised disease. 4 The recently published Prostate Cancer Intervention Versus Observation Trial (PIVOT) -a randomised control trial comparing RP with watchful waiting in 731 US patients with localised prostate cancer disease -showed that RP was associated with reduced all-cause mortality for men with a prostate-specific antigen (PSA) level greater than 10 ng/mL but that it offered no survival benefit to men with a PSA level of 10 ng/mL or less. 5 A systematic review comparing disease-free survival for low dose rate brachytherapy with other treatments for men with clinically localised prostate cancer found no significant difference when compared with RP. 6 Little is known about current patterns of care for men diagnosed with prostate cancer in Australia and whether treatment correlates with clinical practice guidelines. A population-based patterns-of-care survey conducted in Victoria in 1993 showed that 11% of men diagnosed with prostate cancer had received the diagnosis following informal screening and 25% received definitive curative therapy. 7 New South Wales data show that the annual number of PSA tests performed more than doubled, from 184 350 tests in 1996 to 433 187 in 2006. 8 The impact that this has had on patterns of care is unknown.
Our aim was to use the Prostate Cancer Registry to assess patterns of care for men diagnosed with prostate cancer at contributing hospitals in Victoria.
Methods
The methods for data collection, are described elsewhere. 9 Initially, four hospitals (three metropolitan, one regional) contributed data, accounting for about 25% of all Victorian patients with newly diagnosed prostate cancer (calculated based on 2009 incident notification data supplied to the Victorian Cancer Registry). Addition of 13 hospitals in 2010 increased capture to about 75% of newly diagnosed patients in Victoria. With Human Research Ethics Committee approval from the hospitals that contributed data to the Prostate Cancer Registry, prostate cancer notifications that were submitted by these hospitals to the Victorian Cancer Registry are also forwarded to the Prostate Cancer Registry.
Inclusion and exclusion criteria
Men were included in the study if they had been diagnosed with prostate cancer between August 2008 and February 2011 -confirmed pathologically or by a bone, magnetic resonance imaging or computed tomography scan -and were notified to the Prostate Cancer Registry after the date on which the relevant hospital began contributing data. Consent was obtained from clinicians to include patients in the Prostate Cancer Registry. Clinicians were asked to advise the Prostate Cancer Registry if they felt it inappropriate for a patient to be included in the study -for example, for mental health reasons.
Recruitment
An explanatory statement, available in 12 common languages, was sent to men who were eligible to participate in the study about 9 months after they had been diagnosed. The statement invited them to participate in the Prostate Cancer Registry and provided an opt-out option.
Data collection
Histopathological data were captured through hospital information systems and pathology reports. Clinical information -including PSA level at diagnosis and procedure type (including approach) -was captured from medical records by trained data collectors before patients were interviewed over the telephone about their quality of life and to confirm treatment details 12 months after diagnosis. Periodically, hospitals are asked to validate biopsy and radical prostatectomy operations against International Classification of Diseases (10th revision) codes to confirm complete capture of prostate cancer cases by the Prostate Cancer Registry. Treatments provided within 12 months of diagnosis were included in the analysis.
Statistical analysis
Frequencies were used to describe treatment modalities and risk groups, using NCCN risk of disease progression categories (Appendix 1). While the NCCN includes a very low-risk category, this could not be calculated because the Prostate Cancer Registry does not collect PSA density, which is a required parameter in the calculation for very low risk. The Gleason score documented in the histopathology report at the time of biopsy was used in the NCCN algorithm. Where no clinical T stage was recorded but the Gleason score was р 6 and PSA level was < 10 ng/mL, the patient was classified as having disease that was at low risk of progression. Patients were categorised as having no active treatment if their clinical records recorded "active surveillance" or "watchful waiting" and also if there was no documentation of active surveillance or watchful waiting but no treatment was delivered in the within 12 months of diagnosis.
A Pearson's  2 test was used to compare the association between presence of treatment within 12 months of diagnosis and categorical predictor variables of age at diagnosis, risk of disease progression at diagnosis and type of hospital and hospital location attended at diagnosis. These variables were then included in a multivariate logistic regression model. To compare categorical data for the 2008-2011 cohort with 1993 data, 7 a two-sided Fisher exact test was used. Stata/IC 11.0 (StataCorp) was used for all analyses and a two-sided P value < 0.05 was considered to be statistically significant.
Ethics approval
Ethics approval was obtained from the participating hospitals, Monash University and Cancer Council Victoria.
Results
The recruitment of patients for the study is summarised in Box 1. A total of 3268 notifications were received before 1 February 2012 by the Prostate Cancer Registry for the period August 2008 to February 2011. In total, 492 men (15.1%) were ineligible. Of the 2776 who were eligible and for whom treatment data were sought, 52 (1.9%) did not provide consent for participation, leaving 2724 men (98.1%) for whom treatment data were collected and follow-up data were sought. As 697 men were lost to follow-up, confirmation of treatment and PSA levels were obtained for 2027 of the eligible men who provided consent for participation (74.4%). 
Mortality
There were 24 deaths (from all causes) in the period between diagnosis and follow-up -13 deaths in the very highrisk (locally advanced) and metastatic disease category, seven in the clinically localised high-risk category, two in the clinically localised low-risk category and two in the clinically localised intermediate-risk category. There was no significant difference in all-cause mortality according to type of hospital that made the notification (1.2% public [16/1374] Men aged over 75 years were more than 10 times as likely not to receive active treatment compared with those younger than 55 years. Men for whom notifications of prostate cancer were made by private hospitals were significantly less likely to receive active treatment compared with those for whom notifications were made by public hospitals, and men with lowrisk localised disease were significantly less likely to receive active treatment compared with men in all other risk categories. The likelihood of not receiving active treatment was inversely related to risk of disease progression.
From 1993 to 2008-2011, there were notable declines in the median PSA level at diagnosis and the percentage of men receiving no active treatment. However, this comparison is based on different methods of data collection -treatment for men in the 1993 study was determined by surveying the treating clinicians 3 years after diagnosis, whereas our 2008-2011 treatment data were collected 12 months after diagnosis. The proportion of men who had no active treatment in our study (22.7%) is similar to that in a US Medicare-linked study (about 23% for men diagnosed in 2007) 10 and a South Australian study monitoring men treated in the public health system (about 20% of men diagnosed from 1998 to 2007). 11 Men with low-risk disease in our study were four times more likely to receive no treatment compared with men with low-risk disease in 40 urology practices in the United States and recruited to the Cancer of the Prostate Strategic Urologic Research Endeavor (CAPSURE) registry (40.6% v 9%). 12 This suggests that there is less overtreatment of patients with low-risk disease in Victoria compared with the US.
Our finding that almost half of men with clinically localised disease had RP is similar to the 50% rate of RP described for men recruited to the CAPSURE registry. 12 In contrast, much lower rates have been reported elsewhere: 12%-16% in US Medicarelinked reviews (which captured only men older than 64 years and those with a disability or end-stage renal disease), 10, 13 11% in a populationbased dataset from Northern England, 14 23% in the study of men in South Australia who were treated in the public health system, 11 and 13% in the previous study of men in Victoria. 7 Our finding that 71.0% of men received surgery, radiotherapy and/or brachytherapy contrasts with results of the 1993 Victorian study, in which 25% of men received initial treatment with curative intent. 7 Extrapolating this to statewide data using the Victorian Cancer Registry 15 would equate to a sevenfold increase in the number of men having RP, from about 280 in 1993 7 to 2180 in 2010. Similarly, the proportion of men treated with EBRT and high dose rate brachytherapy has increased from 12.0% to 25.6%, or from about 230 men 7 to 1370 men over the same period. In future, we expect that the proportion of men The apparent change in patterns of prostate cancer management in Victoria is consistent with results of studies undertaken in Queensland 16 and New South Wales. 17 In contrast, the institutionally based South Australian registry shows a consistent proportion of men treated with RP (23% over the 1998-2007 study period), or possibly a slight decline. 11 We found that the probability of receiving treatment declined as men aged and as the likelihood of disease progression increased, which is consistent with previous findings. 7, 12 Of particular interest was our finding that having a prostate cancer notification made by a private hospital was an independent factor for not receiving radical treatment, even after age and of risk of disease progression were taken into account. This contrasts the results of a US study, which showed that having private health insurance was associated with higher rates of treatment compared with not having private health insurance. 18 A number of limitations affect the interpretation of our findings. While treatment data were collected for more than 98% of the eligible population, the sample was heavily biased towards men diagnosed and treated at metropolitan hospitals. In addition, hospitals were accrued progressively over the study period, which meant that treatment and outcomes from hospitals that contributed notifications from earlier in the study period were overrepresented. We were unable to interview a quarter of the men diagnosed with prostate cancer 12 months after diagnosis, including all those from non-English speaking backgrounds. This may have resulted in an underestimate of the number of men receiving active treatment and an overestimate of those on active surveillance or watchful waiting. We compared our findings with those from a 1993 patterns-of-care study that collected treatment data over a 3-year period. If our study was extended to include treatment data over a 3-year period, it is likely that an even higher percentage of men would have received active treatment, which would have made the difference between our study and the 1993 study even more pronounced. Another important limitation is that we did not seek to identify reasons why men received no treatment within 12 months of diagnosis. It may be that There has also been a dramatic "stage migration" towards earlier diagnosis of prostate cancer -the vast majority of men in our study were diagnosed with localised disease and only 3.3% were diagnosed with metastatic disease. The Prostate Cancer Registry enables rapid and reliable ascertainment of such data on patterns and quality of care for men diagnosed with prostate cancer and reports patterns-of-care and quality indicator data back to clinicians who have contributed more than 20 cases to the registry via quarterly reports.
